CDKN2A and urinary bladder neoplasm: On this basis, we identified 13/78 cases as p16-altered (17%), which is comparable with the 17–25% reported for bladder tumours in other series (Neihans et al, 1999; Korkolopoulou et al, 2000; Friedrich et al, 2001).